Argus Research Maintains Buy on United Therapeutics, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained a Buy rating on United Therapeutics and raised the price target from $360 to $400.
October 31, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Argus Research has reaffirmed its Buy rating on United Therapeutics and increased the price target from $360 to $400, indicating a positive outlook for the stock.
The increase in the price target from $360 to $400 by Argus Research suggests a strong positive sentiment towards United Therapeutics' future performance. Maintaining a Buy rating further supports the expectation of upward price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100